Address: 780 Cailun Road, Suite 802 Pudong, Shanghai 201203 P.R. China
Tel: 86-21-5132-3312
HUYA Bioscience has developed an innovative approach – the HUYA Integrated Co-development Model – for partnering with Chinese research institutions and pharmaceutical companies to bring promising novel compounds into the Western development process and biopharma market.
HUYA searches for and targets drug compounds that have already demonstrated promising results within China’s SFDA (State Food and Drug Administration, China) testing program and provides a bridge to Western pharmaceutical partners. The data gathered from the SFDA testing provides invaluable guidance regarding the best methods and procedures for FDA and EMEA submissions in the West. Because the compounds have been rigorously evaluated and validated in China, Western partners benefit from streamlined development, lower costs, and greatly reduced risk.
early stage compounds
Your business is very much relationship based here in China. You’ve now established a number of relationships with institutes, universities and companies, but I can imagine that breaking into this…
Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist approach to teambuilding helps it stand out from…
Founded in 2009 by CEO Dr XU Ting, Alphamab started its journey as a protein engineering company with the ultimate dream of becoming, as many Chinese biotechs aspire, a global…
Since the Chinese government unrolled an unprecedented volume-based procurement initiative for essential drugs used in the public hospital system in November 2018 in a bid to curb unsustainable healthcare expenditures,…
A roundup of the latest news from Chinese pharma, including Big Pharma players losing out in the latest round of domestic procurement bidding, updates on Sinopharm’s experimental COVID-19 vaccine, biotech…
The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced since its establishment…
Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
Probably one of the most recognisable Chinese biotechs globally, Zai Lab may only be seven years old but the company has progressed rapidly in becoming a NASDAQ-listed company with not…
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
A roundup of latest news from Chinese pharma and biotech, including a record high share price for Hansoh, strategic healthcare partnerships, venture capital gains, and recent IPO news from Sunshine…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the…
See our Cookie Privacy Policy Here
